ARS Pharmaceuticals, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $-38.3M | $234.0M |
| Jun 2022 | — | $-44.0M | $218.7M |
| Sep 2022 | — | $-50.2M | $203.2M |
| Dec 2022 | — | $272.9M | $210.5M |
| Mar 2023 | — | $261.2M | $87.9M |
| Jun 2023 | — | $248.6M | $119.0M |
| Sep 2023 | — | $237.3M | $60.5M |
| Dec 2023 | — | $230.8M | $71.0M |
| Mar 2024 | — | $223.9M | $56.0M |
| Jun 2024 | — | $215.2M | $36.6M |
| Sep 2024 | — | $201.0M | $39.7M |
| Dec 2024 | $0 | $256.8M | $50.8M |
| Mar 2025 | — | $229.0M | $39.9M |
| Jun 2025 | — | $192.3M | $51.5M |
| Sep 2025 | $96.2M | $147.7M | $59.6M |
| Dec 2025 | $96.4M | $114.3M | $41.3M |
| Mar 2026 | $96.5M | $61.3M | $24.3M |
| Jun 2026 | $96.7M | $12.5M | $8.2M |